Visión generalGráficoNoticiasTraderScreen

BVT Put 200 BIIB 20.12.2024/  DE000VM7SBS5  /

EUWAX
19/11/2024  8:21:34 Diferencia+0.17 Bid12:38:06 Ask12:38:06 Subyacente Precio de ejercicio Fecha de expiración Tipo de opción
3.95EUR +4.50% 3.99
Volumen de oferta: 11,000		 4.08
Tamaño/ Volumen/ Formato de Ask: 11,000		 Biogen Inc 200.00 USD 20/12/2024 Put
TeleTrader 30/10 US opens lower after earnings, jobs, GDP data
TeleTrader 30/10 Biogen's Q3 revenue down 3% to $2.5 billion
Newsfile Corp 10/10 SAGE INVESTOR ALERT: Sage Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to L...
GlobeNewswire 01/09 SAGE INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Sage Therapeutics, Inc. Invest...
GlobeNewswire 29/08 SAGE INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Sage Therapeutics, Inc. Investo...
GlobeNewswire 26/08 Long Term Investor News: Biogen, Seritage Growth, Arbor Realty, and Five Below Investors are Encoura...
GlobeNewswire 26/08 MDA Kicks Off Muscular Dystrophy Awareness Month in September with ‘30 Days of Strength’ Campaign wi...
GlobeNewswire 22/08 Abata Therapeutics Receives FDA Fast Track Designation for ABA-101 for the Treatment of Progressive ...
GlobeNewswire 19/08 Tiziana Life Sciences Appoints New Chief Executive Officer
GlobeNewswire 19/08 Fulcrum Therapeutics Strengthens Leadership Team with the Appointments of Isabel Kalofonos as Chief ...
GlobeNewswire 15/08 Soleno Therapeutics Announces Updates to its Board of Directors
GlobeNewswire 15/08 Abata Therapeutics Announces Strategic Investment from Bristol Myers Squibb Supporting Advancement o...
GlobeNewswire 08/08 Royalty Pharma Reports Second Quarter 2024 Results
GlobeNewswire 01/08 C4 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
TeleTrader 01/08 Biogen books $2.5 billion in Q2 revenue
GlobeNewswire 01/08 Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
GlobeNewswire 31/07 Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease
GlobeNewswire 30/07 New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecane...
GlobeNewswire 30/07 Montara Therapeutics Closes $8 Million Seed Round Led by SV Health Investors’ Dementia Discovery Fun...
GlobeNewswire 30/07 Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Path...
GlobeNewswire 26/07 CVS Health Corporation Investors: Class action lawsuit filed on behalf of investors; the Portnoy Law...
GlobeNewswire 26/07 Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
GlobeNewswire 26/07 BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Long-Term Stockh...
GlobeNewswire 22/07 Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery – Contact The Gross Law Fir...
GlobeNewswire 22/07 DEADLINE ALERT for CMBM, BIIB, DRCT, and FSLY: The Law Offices of Frank R. Cruz Reminds Investors of...